7th International Symposium of Pharmaceutical Sciences "VII SICF" -7th Symposium "Design, Production and Development of Drugs"

7th International Symposium of Pharmaceutical Sciences

VII SICF

DEVELOPMENT OF A STABLE BIOPHARMACEUTICAL FORMULATION FOR A MONOCLONAL ANTIBODY aHER2

The development of pharmaceutical formulations of monoclonal antibodies is of vital importance to achieve effective and safe drugs. Hence, many research groups have focused on using different screening strategies to optimize the formulation for each antibody under study. Within the excipients used to carry out the screening of formulation are carbohydrates, salts, surfactants and amino acids. In our work we focused specifically on a monoclonal antibody aHer2 for the treatment of breast cancer type Her2 positive. For the characterization of these formulations were used methods such as dynamic light scattering, size exclusion chromatography, UV spectrophotometry, among others. As results of the work, was demonstrated the effectiveness of the stepwise screening methodology to select the best formulation variants. In addition, the presence of excipients as carbohydrates improves the stability of the formulation unlike the presence of sodium chloride.

The development of pharmaceutical formulations of monoclonal antibodies is of vital importance to achieve effective and safe drugs. Hence, many research groups have focused on using different screening strategies to optimize the formulation for each antibody under study. Within the excipients used to carry out the screening of formulation are carbohydrates, salts, surfactants and amino acids. In our work we focused specifically on a monoclonal antibody aHer2 for the treatment of breast cancer type Her2 positive. For the characterization of these formulations were used methods such as dynamic light scattering, size exclusion chromatography, UV spectrophotometry, among others. As results of the work, was demonstrated the effectiveness of the stepwise screening methodology to select the best formulation variants. In addition, the presence of excipients as carbohydrates improves the stability of the formulation unlike the presence of sodium chloride.

About The Speaker

Yaiko Saddan Hernández Terrero

MsC. Yaiko Saddan Hernández Terrero

Centro Inmunología Molecular Flag of Cuba
Practical Info
English (US)
Not defined
30 minutes
Not defined
Authors
Katya R. de La Luz
MsC. Yaiko Saddan Hernández Terrero
Julio F. Santo Tomas
Olga L. Fernández
Mileydis Sánchez
Keywords
aher2
biopharmaceutical
characterization
formulation
monoclonal antibody
screening